<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077610</url>
  </required_header>
  <id_info>
    <org_study_id>BA16739</org_study_id>
    <nct_id>NCT00077610</nct_id>
  </id_info>
  <brief_title>A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients</brief_title>
  <official_title>A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of intravenous Mircera, given as maintenance
      treatment for renal anemia in chronic kidney disease patients on dialysis who were previously
      receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target
      sample size is 100-500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period</measure>
    <time_frame>Baseline, Week 29 to Week 36</time_frame>
    <description>A time adjusted mean change in Hb concentration was calculated using an Area Under the Curve (AUC) approach, for both periods separately. Change in Hb concentration between the Baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb from the average evaluation period Hb. At the end of the Week 36, data allowing the evaluation of the therapeutic response was available for 188 out of 221 eligible participants in RO0503821 (1x/2 Weeks) arm; 172 out of 220 eligible participants in RO0503821 (1x/4 Weeks); and 180 out of 225 participants in Epoetin (1-3x/Weeks) arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Maintaining Average Hemoglobin Concentration During Evaluation Period Within +/- 1 Gram Per Deciliter (g/dl) of Average Baseline Hemoglobin Concentration.</measure>
    <time_frame>Baseline, Week 29 to Week 36</time_frame>
    <description>The mean Hb of all values recorded during the evaluation period were calculated, and were subtracted from the mean baseline Hb for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods</measure>
    <time_frame>Week 1 to Week 36</time_frame>
    <description>The number of participants who received RBC transfusions during the titration and evaluation periods were reported .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell Counts (WBC) and Red Blood Cells (RBC)</measure>
    <time_frame>Up to Week 53</time_frame>
    <description>Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for Platelet was 100-550x10^9/Litre [L], for WBC was 3.0-18.0.0x10^9/L, and for RBC was 3.80-6.10x10^12/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes</measure>
    <time_frame>Up to Week 53</time_frame>
    <description>Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for aspartate aminotransferase (AST) was 0-80 (unit per litre [U/L]), alanine aminotransferase (ALT) 0-110 U/L, alkaline phosphatase (ALP) 0-220 U/L, albumin &gt;=30.0 gram/litre (g/L), glucose in non-diabetics 2.80-11.10 (millimol/litre [mmol/L]); potassium 2.90-5.80 mmol/L, and phosphorus 0.75-1.60 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Blood Pressure From Baseline at Week 36 and Week 52</measure>
    <time_frame>Baseline, Week 36 and Week 52</time_frame>
    <description>Blood pressure was measured by manual assessment or automated reading throughout the entire study for every participant. Blood pressure was taken in the sitting position after at least 5 minutes rest. An appropriate -sized cuff was used and both systolic (SBP) and diastolic (DBP) blood pressures were recorded before dialysis (BD) and after dialysis (AD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Pulse Rate (Sitting) From Baseline at Week 36 and Week 52</measure>
    <time_frame>Baseline, Week 36 and Week 52</time_frame>
    <description>Change in pulse rate (beats per minute [bpm]) from baseline values includes only those participants with both a baseline value and a value for specified time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Death</measure>
    <time_frame>Upto Week 53</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes. Overall deaths occurred in the study were reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">673</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>RO0503821 (1x/2 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RO0503821 (1x/4 Weeks)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin (1-3x/Weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa or beta</intervention_name>
    <description>intravenously 3 times weekly for 52 weeks, as prescribed</description>
    <arm_group_label>Epoetin (1-3x/Weeks)</arm_group_label>
    <other_name>Epoetin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO0503821 (1x/2 Weeks)</intervention_name>
    <description>60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.</description>
    <arm_group_label>RO0503821 (1x/2 Weeks)</arm_group_label>
    <other_name>Mircera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO0503821 (1x/4 Weeks)</intervention_name>
    <description>120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.</description>
    <arm_group_label>RO0503821 (1x/4 Weeks)</arm_group_label>
    <other_name>Mircera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients &gt;=18 years of age;

          -  chronic renal anemia;

          -  on dialysis therapy for at least 12 weeks before screening;

          -  receiving IV epoetin for at least 8 weeks before screening.

        Exclusion Criteria:

          -  women who are pregnant, breastfeeding or using unreliable birth control methods;

          -  administration of another investigational drug within 4 weeks before screening, or
             during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816-5119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116-1906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-1718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <zip>27157-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1H 3G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aubervilliers</city>
        <zip>93307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75 016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ellwangen</city>
        <zip>73479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <zip>90431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <zip>70191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesloch</city>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lecco</city>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodi</city>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Levanger</city>
        <zip>7600</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lillehammer</city>
        <zip>2629</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1003</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2004</study_first_posted>
  <results_first_submitted>January 29, 2016</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 673 participants were recruited at 91 centers in 8 countries with chronic renal anemia and dialysis therapy for at least 12 weeks before screening and during the screening/baseline period. This study was conducted between February 25, 2004 and August 17, 2005</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RO0503821 (1x/2 Weeks)</title>
          <description>Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="P2">
          <title>RO0503821 (1x/4 Weeks)</title>
          <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="P3">
          <title>Epoetin (1-3x/Weeks)</title>
          <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Renal transplant</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew from dialysis care</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple blood transfusions</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal Investigator's decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of health condition</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Given Epogen in hospital</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to other unit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to nursing home</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to satellite unit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to other center for surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in dialysis modality</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Financial issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsors decision to withdraw</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety population included all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not.</population>
      <group_list>
        <group group_id="B1">
          <title>RO0503821 (1x/2 Weeks)</title>
          <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="B2">
          <title>RO0503821 (1x/4 Weeks)</title>
          <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="B3">
          <title>Epoetin (1-3x/Weeks)</title>
          <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="221"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="225"/>
            <count group_id="B4" value="666"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="15.05"/>
                    <measurement group_id="B2" value="59.0" spread="15.00"/>
                    <measurement group_id="B3" value="58.5" spread="15.16"/>
                    <measurement group_id="B4" value="58.9" spread="15.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period</title>
        <description>A time adjusted mean change in Hb concentration was calculated using an Area Under the Curve (AUC) approach, for both periods separately. Change in Hb concentration between the Baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb from the average evaluation period Hb. At the end of the Week 36, data allowing the evaluation of the therapeutic response was available for 188 out of 221 eligible participants in RO0503821 (1x/2 Weeks) arm; 172 out of 220 eligible participants in RO0503821 (1x/4 Weeks); and 180 out of 225 participants in Epoetin (1-3x/Weeks) arm.</description>
        <time_frame>Baseline, Week 29 to Week 36</time_frame>
        <population>The Per Protocol population included all randomized participants except those not meeting inclusion criterion related to Hb parameters and &lt;5 recorded Hb values during the evaluation period with missing administrations of the study drug/ reference drug. Please refer to the outcome measure description section for more details.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 120,180 mcg) that was based on the Epoetin dose administered (&lt;8000, 8000-16000, &gt;16000 IU/Week) during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Week)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period</title>
          <description>A time adjusted mean change in Hb concentration was calculated using an Area Under the Curve (AUC) approach, for both periods separately. Change in Hb concentration between the Baseline and evaluation periods was calculated by subtracting the calculated average baseline Hb from the average evaluation period Hb. At the end of the Week 36, data allowing the evaluation of the therapeutic response was available for 188 out of 221 eligible participants in RO0503821 (1x/2 Weeks) arm; 172 out of 220 eligible participants in RO0503821 (1x/4 Weeks); and 180 out of 225 participants in Epoetin (1-3x/Weeks) arm.</description>
          <population>The Per Protocol population included all randomized participants except those not meeting inclusion criterion related to Hb parameters and &lt;5 recorded Hb values during the evaluation period with missing administrations of the study drug/ reference drug. Please refer to the outcome measure description section for more details.</population>
          <units>gram per deciliter (g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="1.06"/>
                    <measurement group_id="O2" value="0.01" spread="0.96"/>
                    <measurement group_id="O3" value="-0.10" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority test for treatment differences in Hb change from baseline, based on analysis of co-variance (ANCOVA) analysis with a non-inferiority limit of -0.75 g/dL.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two RO0503821 dosing schedules were compared separately to epoetin reference using ANCOVA, with Hb at BL and region as the covariates. The test for non-inferiority was based on the lower limit of the two-sided 97.5% confidence interval for the difference between the two groups. When the lower limit was greater than or equal to –0.75 g/dL, the RO0503821 groups were regarded as non-inferior to the epoetin reference group. The confidence level of 97.5% was chosen to adjust for multiplicity.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA, CI for difference between groups</method>
            <param_type>Mean Difference between groups</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0973</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.215</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Difference between groups based on the adjusted means derived from the ANCOVA model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The non-inferiority test for treatment differences in Hb change from baseline, based on ANCOVA analysis with a non-inferiority limit of -0.75 g/dL.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The two RO0503821 dosing schedules were compared separately to epoetin reference using ANCOVA, with Hb at BL and region as the covariates. The test for non-inferiority was based on the lower limit of the two-sided 97.5% confidence interval for the difference between the two groups. When the lower limit was greater than or equal to -0.3 g/dL, the RO0503821 groups were regarded as non-inferior to the epoetin reference group. The confidence level of 97.5% was chosen to adjust for multiplicity.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA, CI for difference between groups</method>
            <param_type>Mean Difference between groups</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0997</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.173</ci_lower_limit>
            <ci_upper_limit>0.275</ci_upper_limit>
            <estimate_desc>Difference between groups based on the adjusted means derived from the ANCOVA model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Maintaining Average Hemoglobin Concentration During Evaluation Period Within +/- 1 Gram Per Deciliter (g/dl) of Average Baseline Hemoglobin Concentration.</title>
        <description>The mean Hb of all values recorded during the evaluation period were calculated, and were subtracted from the mean baseline Hb for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given.</description>
        <time_frame>Baseline, Week 29 to Week 36</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all randomized participants. At the end of Week 36, data allowing the evaluation of the therapeutic response was available for 196/221, 188/220, and 205/225 participants in RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks), and Epoetin (1 -3x/Weeks), respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 100,180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Maintaining Average Hemoglobin Concentration During Evaluation Period Within +/- 1 Gram Per Deciliter (g/dl) of Average Baseline Hemoglobin Concentration.</title>
          <description>The mean Hb of all values recorded during the evaluation period were calculated, and were subtracted from the mean baseline Hb for each participant. The number of participants maintaining their average Hb within +/- 1 g/dL of their average baseline hemoglobin concentration is given.</description>
          <population>The intent-to-treat (ITT) population was defined as all randomized participants. At the end of Week 36, data allowing the evaluation of the therapeutic response was available for 196/221, 188/220, and 205/225 participants in RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks), and Epoetin (1 -3x/Weeks), respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods</title>
        <description>The number of participants who received RBC transfusions during the titration and evaluation periods were reported .</description>
        <time_frame>Week 1 to Week 36</time_frame>
        <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not.</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 100,180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods</title>
          <description>The number of participants who received RBC transfusions during the titration and evaluation periods were reported .</description>
          <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell Counts (WBC) and Red Blood Cells (RBC)</title>
        <description>Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for Platelet was 100-550x10^9/Litre [L], for WBC was 3.0-18.0.0x10^9/L, and for RBC was 3.80-6.10x10^12/L.</description>
        <time_frame>Up to Week 53</time_frame>
        <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 100,180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell Counts (WBC) and Red Blood Cells (RBC)</title>
          <description>Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for Platelet was 100-550x10^9/Litre [L], for WBC was 3.0-18.0.0x10^9/L, and for RBC was 3.80-6.10x10^12/L.</description>
          <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Platelet (n=218, 216, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Platelet (n=218, 216, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC (n=218, 217, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC (n=218, 217, 223)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High RBC (n=124, 129, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low RBC (n=124, 129, 89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes</title>
        <description>Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for aspartate aminotransferase (AST) was 0-80 (unit per litre [U/L]), alanine aminotransferase (ALT) 0-110 U/L, alkaline phosphatase (ALP) 0-220 U/L, albumin &gt;=30.0 gram/litre (g/L), glucose in non-diabetics 2.80-11.10 (millimol/litre [mmol/L]); potassium 2.90-5.80 mmol/L, and phosphorus 0.75-1.60 mmol/L</description>
        <time_frame>Up to Week 53</time_frame>
        <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 100,180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes</title>
          <description>Marked laboratory abnormalities were defined as those values that were outside the Roche marked abnormality reference range. These abnormality laboratory values were flagged as Low or High if they were below the lower limit or above the upper limit of Roche marked abnormality reference range, respectively. The marked abnormality reference range for aspartate aminotransferase (AST) was 0-80 (unit per litre [U/L]), alanine aminotransferase (ALT) 0-110 U/L, alkaline phosphatase (ALP) 0-220 U/L, albumin &gt;=30.0 gram/litre (g/L), glucose in non-diabetics 2.80-11.10 (millimol/litre [mmol/L]); potassium 2.90-5.80 mmol/L, and phosphorus 0.75-1.60 mmol/L</description>
          <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALT. (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Phosphate (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Phosphate (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium (n=218, 216, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (n=218, 215, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Blood glucose in non-diabetic (n=114,131,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Blood Glucose in Non-Diabetic (n=114,131,110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Blood Pressure From Baseline at Week 36 and Week 52</title>
        <description>Blood pressure was measured by manual assessment or automated reading throughout the entire study for every participant. Blood pressure was taken in the sitting position after at least 5 minutes rest. An appropriate -sized cuff was used and both systolic (SBP) and diastolic (DBP) blood pressures were recorded before dialysis (BD) and after dialysis (AD).</description>
        <time_frame>Baseline, Week 36 and Week 52</time_frame>
        <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 100,180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Blood Pressure From Baseline at Week 36 and Week 52</title>
          <description>Blood pressure was measured by manual assessment or automated reading throughout the entire study for every participant. Blood pressure was taken in the sitting position after at least 5 minutes rest. An appropriate -sized cuff was used and both systolic (SBP) and diastolic (DBP) blood pressures were recorded before dialysis (BD) and after dialysis (AD).</description>
          <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in SBP, BD at Wk 36 (n=189, 178,196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="25.3"/>
                    <measurement group_id="O2" value="-2" spread="22.7"/>
                    <measurement group_id="O3" value="3" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SBP, BD at Wk 52 (n=168, 166, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0" spread="24.6"/>
                    <measurement group_id="O2" value="-3" spread="24.6"/>
                    <measurement group_id="O3" value="1" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in DBP, BD at Wk 36 (n=189, 178, 195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="14.7"/>
                    <measurement group_id="O2" value="-3" spread="16.3"/>
                    <measurement group_id="O3" value="1" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in DBP, BD at Wk 52 (n=168, 166, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="15.2"/>
                    <measurement group_id="O2" value="-3" spread="18.3"/>
                    <measurement group_id="O3" value="-1" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SBP, AD at Wk 36 (n=189, 177, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="28.3"/>
                    <measurement group_id="O2" value="-1" spread="27.0"/>
                    <measurement group_id="O3" value="-0" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in SBP, AD at Wk 52 (n=167, 168, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="24.5"/>
                    <measurement group_id="O2" value="-0" spread="29.3"/>
                    <measurement group_id="O3" value="1" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in DBP, AD at Wk 36 (n=189, 177, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="16.4"/>
                    <measurement group_id="O2" value="-0" spread="15.2"/>
                    <measurement group_id="O3" value="-2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in DBP, AD at Wk 52 (n=167, 168, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="14.9"/>
                    <measurement group_id="O2" value="-0" spread="15.9"/>
                    <measurement group_id="O3" value="-3" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Pulse Rate (Sitting) From Baseline at Week 36 and Week 52</title>
        <description>Change in pulse rate (beats per minute [bpm]) from baseline values includes only those participants with both a baseline value and a value for specified time period.</description>
        <time_frame>Baseline, Week 36 and Week 52</time_frame>
        <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (60, 100,180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pulse Rate (Sitting) From Baseline at Week 36 and Week 52</title>
          <description>Change in pulse rate (beats per minute [bpm]) from baseline values includes only those participants with both a baseline value and a value for specified time period.</description>
          <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from BL at Week 36 (n=188, 176, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="12.0"/>
                    <measurement group_id="O2" value="2" spread="11.8"/>
                    <measurement group_id="O3" value="0" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from BL at Week 52 (n=168, 166, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="13.6"/>
                    <measurement group_id="O2" value="1" spread="13.4"/>
                    <measurement group_id="O3" value="-1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Death</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator’s judgment or requires intervention to prevent one or other of these outcomes. Overall deaths occurred in the study were reported.</description>
        <time_frame>Upto Week 53</time_frame>
        <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
        <group_list>
          <group group_id="O1">
            <title>RO0503821 (1x/2 Weeks)</title>
            <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O2">
            <title>RO0503821 (1x/4 Weeks)</title>
            <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants randomized received a starting dose of RO0503821 (120, 200, 360 mcg) that was based on the Epoetin dose administered during the week preceding the switch to the study drug.</description>
          </group>
          <group group_id="O3">
            <title>Epoetin (1-3x/Weeks)</title>
            <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Death</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator’s judgment or requires intervention to prevent one or other of these outcomes. Overall deaths occurred in the study were reported.</description>
          <population>The Safety Population was defined as all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not. Participants available at particular time point were included in the analysis (n).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 53</time_frame>
      <desc>Of 673 recruited participants, 7 withdrew before receiving the study drug (2 in the RO0503821 [1x/2 Weeks], 4 in the RO0503821 [1x/4 Weeks] and 1 from Epoetin group). The safety population included all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not.</desc>
      <group_list>
        <group group_id="E1">
          <title>RO0503821 (1x/2 Weeks)</title>
          <description>Participants received RO0503821 once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="E2">
          <title>RO0503821 (1x/4 Weeks)</title>
          <description>Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (&lt;8000, 8000-16000, &gt;16000 IU/Week) administered during the week preceding the switch to the study drug.</description>
        </group>
        <group group_id="E3">
          <title>Epoetin (1-3x/Weeks)</title>
          <description>Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 8.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardio respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Aortic valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bronchitis acute viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Postoperative infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bursa disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Essential thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin’s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Benign intracranial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital-digestive tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diabetic dermopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Aneurysm arteriovenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Hypoperfusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Ver 8.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

